| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 1/200 - 1/1000 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | UV20; COFS4; RAD10 |
| Entrez GeneID | 2067 |
| clone | 2F3A2 |
| WB Predicted band size | 32.6kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human ERCC1 (AA: 1-120) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于ERCC1抗体的3篇代表性文献，涵盖抗体验证、临床应用及技术争议：
---
1. **文献名称**：*Validation of Antibodies for the Specific Detection of ERCC1 in Human Tissues*
**作者**：Bhagwat NR et al.
**摘要**：该研究评估了多种市售ERCC1抗体的特异性，发现部分抗体存在交叉反应性(如与PCNA等蛋白结合)，导致免疫组化结果不可靠。强调选择经过验证的抗体对准确评估ERCC1表达至关重要，尤其在癌症预后分析中。
---
2. **文献名称**：*ERCC1 Expression as a Prognostic Marker in Advanced Ovarian Cancer*
**作者**：Olaussen KA et al.
**摘要**：通过免疫组化分析卵巢癌患者肿瘤样本中的ERCC1蛋白表达，发现高表达ERCC1与铂类化疗耐药性显著相关，提示ERCC1可能作为预测化疗反应的生物标志物，但强调需结合分子检测以提高准确性。
---
3. **文献名称**：*ERCC1 Antibody Discrepancies and Their Impact on Clinical Trials*
**作者**：Friboulet L et al.
**摘要**：比较不同ERCC1抗体(如8F1、4F9)在非小细胞肺癌中的检测结果差异，发现部分抗体无法区分ERCC1的功能亚型，可能导致临床研究中结论矛盾。呼吁标准化抗体选择及检测流程。
---
**扩展提示**：
- 部分文献指出ERCC1 mRNA与蛋白表达水平可能不一致，需结合多组学数据。
- 近年研究倾向使用质谱或基因编辑技术(如CRISPR敲除)验证抗体特异性。
- 参考数据库(如Human Protein Atlas)可辅助评估抗体适用性。
ERCC1 (Excision Repair Cross-Complementation Group 1) is a critical protein involved in DNA repair, specifically in the nucleotide excision repair (NER) pathway. It forms a heterodimeric complex with XPF (xeroderma pigmentosum group F), enabling the incision of damaged DNA strands during repair processes. ERCC1’s role in maintaining genomic stability has made it a focus in cancer research, particularly in understanding chemoresistance. Tumors with high ERCC1 expression often exhibit resistance to platinum-based chemotherapy (e.g., cisplatin, oxaliplatin), as these drugs rely on creating DNA crosslinks that ERCC1-XPF helps repair.
ERCC1 antibodies are essential tools for detecting and quantifying ERCC1 protein levels in research and clinical settings. They are widely used in immunohistochemistry (IHC), Western blotting, and ELISA to assess ERCC1 expression in tumor tissues. Clinically, such antibodies aid in predicting patient responses to platinum therapies, guiding personalized treatment strategies. However, variability in antibody specificity and validation methods has led to debates about their reliability in diagnostic applications. Some studies highlight discrepancies in ERCC1 isoform detection, emphasizing the need for standardized antibody validation protocols. Despite these challenges, ERCC1 antibodies remain pivotal in exploring DNA repair mechanisms, cancer biology, and therapeutic resistance, bridging molecular insights with clinical oncology.
×
